Tudor Investment Corp
KDNY

Tudor Investment Corp’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Tudor Investment Corp’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,211
Closed -$661K – 3086
2022
Q4 		$661K Sell
25,211
-6,184
-20% -$137K 0.01% 1405
2022
Q3 		$617K Sell
31,395
-3,208
-9% -$64.3K 0.01% 1249
2022
Q2 		$605K Buy
+34,603
New +$543K 0.02% 1174
2020
Q1 		– Sell
-12,421
Closed -$73K – 1403
2019
Q4 		$73K Hold
12,421
– – ﹤0.01% 1068
2019
Q3 		$66K Hold
12,421
– – ﹤0.01% 1022
2019
Q2 		$96K Buy
12,421
+3,797
+44% +$57.8K ﹤0.01% 1030
2019
Q1 		$172K Buy
8,624
+4,654
+117% +$81.2K 0.01% 1016
2018
Q4 		$52K Buy
+3,970
New +$79.3K ﹤0.01% 956
2017
Q4 		– Sell
-3,341
Closed -$178K – 1336
2017
Q3 		$178K Buy
+3,341
New +$199K ﹤0.01% 975
2017
Q2 		– Sell
-3,087
Closed -$166K – 1450
2017
Q1 		$166K Buy
3,087
+797
+35% +$45K 0.01% 1259
2016
Q4 		$131K Buy
+2,290
New +$139K ﹤0.01% 1285

Other funds holding KDNY

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Tudor Investment Corp's KDNY Position: Q1 2023 in Review

Tudor Investment Corp sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q1 2023, closing a stake of 25,211 shares — an estimated $661K sold.

Tudor Investment Corp first reported a position in KDNY in Q4 2016 and held it in 11 quarters. The position peaked at $661K in Q4 2022. 157 funds tracked by Wall St. Rank hold KDNY as of Q1 2023.

  • Tudor Investment Corp reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Tudor Investment Corp sold 25,211 Chinook Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $661K.
  • Tudor Investment Corp first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2016 and held it in 11 quarters.
  • Tudor Investment Corp's Chinook Therapeutics, Inc. Common Stock position peaked at $661K in Q4 2022.
  • 157 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Tudor Investment Corp's 13F filing for Q1 2023, filed 15 May 2023.